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autoantibodies in early rheumatoid arthritis
Julie K Laustsen1,2*, Tue K Rasmussen1,2, Kristian Stengaard-Pedersen2,3, Kim Hørslev-Petersen4, Merete L Hetland5,6,
Mikkel Østergaard5,6, Peter Junker7, Malene Hvid1,3 and Bent Deleuran1,2,3Abstract
Introduction: OX40 and its ligand OX40L are key components in the generation of adaptive memory response and
provide necessary co-stimulatory signals for activated effector T cells. Here we investigate the dual roles of the
membrane and soluble (s) forms of OX40 and OX40L in plasma and synovial fluid and their association with
autoantibodies and disease activity in rheumatoid arthritis (RA).
Methods: Soluble OX40 and sOX40L plasma levels were measured in treatment-naïve early RA patients (eRA) at
baseline and after 3, 6, and 12 months of treatment with methotrexate and adalimumab (n = 39) and with
methotrexate alone (n = 37). Adalimumab was discontinued after the first year, and patients were followed for
additional 12 months. For comparison, sOX40 and sOX40L were measured in patients with chronic RA (cRA, n = 15)
and healthy volunteers (HV, n = 34). Membrane-bound OX40 and OX40L expression on T cells, B cells and
monocytes were quantified.
Results: Soluble OX40 plasma levels of eRA patients were not different at the time of treatment initiation, but
were significantly higher after 12 months of treatment, compared with HV or cRA patients. Soluble OX40L was
significantly elevated throughout the first 12 months of treatment compared with HVs and patients with cRA.
Adalimumab treatment did not influence sOX40 or sOX40L plasma levels. At baseline, sOX40L levels were strongly
associated with the presence of anti-citrullinated protein antibodies (ACPA) (P <0.001) and IgM-RF (P <0.0001). The
sOX40/sOX40L ratio was decreased in eRA, and a low ratio at the time of adalimumab discontinuation was
associated with increased DAS28CRP and risk of flare the following year. T cells in the synovial fluid had the
highest expression of OX40, while monocytes and B cells were the main expressers of OX40L in the joint.
Conclusions: Plasma levels of sOX40 and sOX40L were increased in eRA and sOX40L was correlated with ACPA
and IgM-RF. Further, expression of membrane-bound OX40 and OX40L was increased in eRA and cRA. Combined,
these findings could reflect that increased activity in the OX40 systems facilitate to drive disease activity and
autoantibody production in RA.
Trial registration: Clincaltrials.gov NCT00660647, 10 April 2008.Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune
disease affecting about 0.8% of the adult population. It is
characterized by synovitis and progressive destruction of
the joints accompanied by multiple systemic symptoms.
Autoantibodies occur in 60 to 80% of patients, suggesting* Correspondence: jkl@biomed.au.dk
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stated.a pivotal role for adaptive immune responses in the patho-
genesis [1]. This is supported by the presence of increased
amounts of CD4 + CD45RO+T cells in the RA synovium.
Several members of the TNF superfamily play an im-
portant role for the generation of an optimal memory re-
sponse; among these are OX40 and its ligand, OX40L
[2-5]. OX40 is transiently induced on T cells upon antigen
activation, while OX40L is expressed by a variety of cells,
most abundantly on antigen-presenting cells (APCs) [6-9].
OX40 provides a co-stimulatory signal to activated
effector T cells and is crucial for the generation ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ity [9]. The generation of memory T cells is achieved
through the NF-κB pathway by induction of anti-
apoptotic factors [3]. The importance of the OX40/
OX40L axis in memory generation and autoimmunity
has been demonstrated in several animal studies where
OX40- or OX40L-deficient mice have been shown to
have an impaired memory response [8,10,11]. In addition
to T cells, a recent study using a graft versus host model
supports the role of OX40 in B cell activation. Here,
OX40 stimulation induced production of donor-reactive
alloantibodies in the absence of CD40 [12].
The TNF superfamily is known to induce bidirectional
signals and this also applies to OX40/OX40L [13]. In
addition to serving as a ligand, OX40L is a counter re-
ceptor, which initiates reverse signals in the cell and reg-
ulates cytokine production and IgG class switch [14]. In
accordance with this, the OX40/OX40L binding axis
assumes an important role in sustaining an ongoing
memory-prone immune response, and it is believed to
be important in the pathogenesis of autoimmune dis-
eases like RA. In support of this, animal studies demon-
strate the presence of OX40 and OX40L in synovial
tissue and reveal that endogenous OX40L plays a pro-
inflammatory role in collagen II-induced arthritis in
mice as administration of anti-OX40L mAb ameliorates
the disease severity [15,16]. Besides their membrane-
bound isoforms, OX40 and OX40L are both present in
soluble forms (sOX40 and sOX40L) that have previously
been linked to autoimmune diseases [2,4]. The bioactive
nature of these soluble forms is supported by reports
that sOX40 is antagonistic to the membrane-bound
form because it inhibits the inflammatory response and
thus, mimics the T regulatory (T-reg) function [6,8].
Based on the above, we hypothesize that RA patients
show signs of activity in the OX40 system. To investigate
this, we measure the plasma levels of soluble OX40
and OX40L in a closely monitored cohort of early RA
patients and compare with chronic RA patients and
healthy volunteers, and examine the association between
these soluble isoforms, autoantibodies and clinical dis-
ease parameters. We further measure the expression
levels of the membrane-bound isoforms on cells from
peripheral blood and synovial fluid.
Materials and methods
Patient samples
A sample set of ethylenediaminetetraacetic acid (EDTA)-
stabilized plasma samples was obtained from a Danish
randomized controlled trial (RCT), optimized treatment
algorithm in early rheumatoid arthritis (OPERA) (n = 76),
which included RA patients with a disease duration of less
than 6 months [12]. Samples were selected in a blinded,
non-stratified manner from a longitudinal set of steroid-and disease-modifying anti-rheumatic drug (DMARD)-
naïve RA patients (eRA) (n = 76) from whom samples
were obtained at baseline (time of diagnosis) and after 3,
6, and 12 months of treatment. All patients received
methotrexate (MTX) in combination with either adalimu-
mab (ADA, n = 39) or placebo (PLA, n = 37). If patients
presented with swollen joints during the first year, they
were treated with intra-articular triamcinolone injections.
Biochemical and clinical diseases parameters were mea-
sured and collected at baseline, and at 3 months and
12 months of treatment (Table 1). IgM rheumatoid factor
(IgM-RF) and anti-citrullinated peptide antibody (ACPA)
were measured by ELISA, the latter by using second-
generation cyclic citrullinated peptide as antigen (Phadia,
Uppsala, Sweden). After the first year of treatment, adali-
mumab was discontinued and patients were followed for
disease activity for another 12 months. In this study, we
defined a flare as an increased score for CRP-based disease
activity in 28 joints (DAS28CRP) >1.2 if DAS28CRP <3.2
or >0.6 if DAS28CRP ≥3.2 according to van der Maas
et al. [17]. EDTA plasma samples from healthy volunteers
(HV, n = 34) matched for age and gender with the OPERA
patients were obtained from blood donors at the blood
bank, Aarhus University Hospital.
A cross-sectional sample set was collected from chronic
RA (cRA) patients (n = 15) including peripheral blood
mononuclear cells (PBMC) with paired synovial fluid
mononuclear cells (SFMC) from the outpatient clinic at
Aarhus University Hospital. All cRA patients had disease
duration of more than 8 years. PBMCs from HV served as
a control group (HV, n = 10). In comparison we collected
a cross-sectional sample set of PBMC from eRA patients
with disease duration less than 6 months (n = 5) from the
outpatient clinic at Aarhus University Hospital.
PBMC and SFMC from EDTA-stabilized whole blood
and synovial fluid, respectively, were isolated by density
gradient centrifugation using Ficoll-Paque PLUS and
stored at −150°C until use. Plasma was stored at −80°C
until time of analysis.
Ethics
The studies were approved by the Danish Medical Agency
(2612-3393), the Danish Data Protection Agency (2007-
41-0072 and 2011-41-6863), and the Regional Ethics
Committee (VEK-20070008, 1-10-72-291-12 and 1-10-72-
189-13). All patients gave written consent to participate in
the study in accordance with the Declaration of Helsinki
and carried out according to the principles of the Inter-
national Conference on Harmonization guidelines for
good clinical practice (GCP, 1996 revision).
ELISA
Plasma levels of sOX40 were quantified using a sOX40
ELISA kit (catalog number BMS296, eBioscience, San
Table 1 Characteristics of patients and controls
Characteristics Early rheumatoid
arthritis PLA (n = 37)
Early rheumatoid
arthritis ADA (n = 39)
Chronic rheumatoid
arthritis (n = 15)
Healthy
volunteers (n = 34)
Age, years 54 (37 to 65) 56 (38 to 62) 56 (45 to 64) 54 (38 to 62)
Gender, % female 78 64 80 67
Disease duration at inclusion, months 2.7 (1.4 to 4.3) 2.9 (1.6 to 4.4) 234 (120 to 342) NA
Disease scores
DAS28 score, baseline 5.6 (4.9 to 5.8) 5.4 (4.8 to 6.4) 3.0 (2.2 to 3.9) NA
DAS28 score, 3 months 2.3 (1.9 to 2.9) 2.0 (1.8 to 2.7) NA NA
DAS28 score, 12 months 2.2 (1.9 to 3.4) 1.9 (1.8 to 2.5) NA NA
Remission, 12 months, % 56 52 NA NA
HAQ score, baseline, range 0 to 3 0.9 (0.6 to 1.3) 1.1 (0.8 to 1.5) 1.0 (0.2 to 2.0) NA
HAQ score, 3 months, range 0 to 3 0.1 (0.0 to 0.6) 0.2 (0.0 to 0.38) NA NA
HAQ score, 12 months, range 0 to 3 0.1 (0 to 0.5) 0.0 (0.0 to 0.4) NA NA
Treatment dose
MTX, 12 months, mg/week 20.0 (15.5 to 20.0) 20.0 (18.8 to 20.0) NA NA
Cumulative dose of intra-articular betamethasone,
12 months, ml
8.0 (5.0 to 12.5) 5.0 (3.0 to 10.0) NA NA
Laboratory findings at baseline
IgM-RF-positive, % 84 67 74 NA
ACPA-positive, % 81 56 74 NA
Results are presented as median (SD) or percent. Statistical difference in anti-citrullinated protein antibody (ACPA)-positive in the patient group receiving placebo
and methotrexate (PLA) and the patient group receiving adalimumab and methotrexate (ADA) at baseline (P <0.05). MTX, methotrexate; ADA, adalimumab; CRP,
C-reactive protein; DAS28, disease activity score in 28 joints; DAS28CRP, CRP-based DAS28; Remission, American College of Rheumatology/European League
Against Rheumatism remission (Boolean, 28 joints); HAQ, health assessment questionnaire; IgM-RF, IgM rheumatoid factor; NA, not applicable or not available.
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description with the following modifications: samples were
diluted in sample diluent supplemented with human, mu-
rine and bovine IgG (all from Jackson Immunoresearch,
West Grove, PA, USA) added in excess to ensure pre-
aggregation of heterophilic antibodies in the samples [18];
samples and standards were added to the wells and incu-
bated overnight at 4°C; after adding biotin-conjugated de-
tection antibody, the plates were incubated with ELAST
enhancement kit (PerkinElmer, Waltham, MA, USA) and
washed seven times before adding tetramethylbenzidine
(TMB). All samples were analyzed in duplicates using the
average optical density (OD) values to calculate concen-
trations (minimum detection level (cutoff) 5.97 pg/ml).
A sOX40L ELISA was constructed, optimized, and vali-
dated in-house. Maxisorb ELISA plates (NUNC, Roskilde,
Denmark) were coated with a monoclonal mouse anti-
OX40L antibody (MAB10541, R&D Systems, Minneapolis,
MN, USA) diluted in PBS at a concentration of 4 ug/ml
and blocked with ELISA blocking buffer (10% skimmed
milk powder in PBS). Samples and standards (recombinant
sOX40L, catalog number 310-28, Peprotech, Rocky Hill,
NJ, USA) diluted 1:2 in PBS were added in duplicate and
incubated overnight at 4°C. As above, all samples werepre-incubated with human, murine and bovine IgG in ex-
cess to ensure pre-aggregation of heterophilic antibodies.
A biotinylated monoclonal mouse anti-OX40L (ANC10G1,
Lifespan Biosciences, Seattle, WA, USA) was used as
detection antibody at a concentration of 1 ug/ml in PBS.
The minimal detectable concentration was 1.16 ng/ml for
sOX40L.
Both ELISAs were spiked with variable concentrations
of sOX40 and sOX40L, respectively. Recovery was >80%
in all cases (data not shown). Furthermore, the samples
were tested for the presence of sOX40/sOX40L dimers
by adding the detection antibody from the sOX40
ELISA; this gave blank readings (data not shown). The
cutoff of both ELISAs was calculated as the average
value of blanks plus two SDs of the blanks. Values below
the cutoffs were assigned the value of the cutoff.
OX40 and OX40L flow cytometry
For this study, paired SFMC and PBMC samples from
cRAs (n = 15) and PBMC samples from eRA (n = 5)
and HVs (n = 10) were analyzed for the expression of
OX40 and sOX40L. Surface staining was performed
on unstimulated cells using mouse monoclonal anti-
bodies against OX40 (clone MOPC-21, BD Biosciences,
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Systems, Minneapolis, MN, USA), CD4 (clone RPA-T4, BD
Biosciences), CD45RO (clone UCHL1, Beckman Coulter,
Brea, CA, USA), CD14 (clone MϕP9, BD Biosciences),
and CD19 (clone HD37, Dako Cytomation, Glostrup,
Denmark). All antibodies were titrated to the optimal
working concentrations. All samples were blocked for
unspecific binding by preincubation with 10% heat-
inactivated murine serum (in-house production). Gating
of OX40 and OX40L was done using fluorescence minus-
one (FMO) controls combined with the relevant isotype
controls (FMO/iso) matched for species, IgG subtype,
fluorochrome and concentration. All flow cytometric
analyses were performed within 24 hours using the
LSRFortessa with Diva 7 software (BD Biosciences) and
FlowJo software (Tree Star Inc., Ashland, OR, USA). For
gating strategy, please see Additional file 1: Figure S1.
Statistics
Statistical analyses were performed using GraphPad Prism
6.0 for Mac (GraphPad Software, La Jolla, CA, USA). All
data were analyzed by non-parametric statistics. Paired
data were analyzed using the Wilcoxon signed-rank test.
Non-paired data were analyzed by the Mann-Whitney
U-test. Data were correlated using Spearman’s Rho. All
data are expressed as median and IQR and 25th to 75th
percentiles, unless otherwise specified. In all tests, the
level of significance was a two-sided P-value <0.05.eR
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Soluble OX40 and sOX40L plasma levels are increased in
eRA patients compared with HV
In the initial experiments, we wanted to determine the
plasma level of sOX40 in eRA patients and to compare
this level with the corresponding levels in cRA patients
and HV. At the time of treatment initiation, eRA pa-
tients’ sOX40 levels were similar to those of cRA and
HV. During the first treatment year sOX40 levels in-
creased from 5.97 pg/ml (5.97 pg/ml to 7.14 pg/ml) at
baseline to 11.47 pg/ml (7.69 pg/ml to 13.68 pg/ml) at
12 months (P <0.001), and sOX40 levels at 12 months
were also significantly higher than those of cRA pa-
tients (5.97 pg/ml (5.97 pg/ml to 10.03 pg/ml) and HV
(5.97 pg/ml (5.97 pg/ml to 17.34 pg/ml)) (both P <0.01,
Figure 1A).
Plasma levels of sOX40L in eRA patients were signifi-
cantly elevated throughout the first treatment year with
a bimodal concentration curve where the highest levels
were reached upon treatment initiation (18.30 ng/ml
(2.59 ng/ml to 57.54 ng/ml)). This was followed by an
83% decrease after 3 months (3.06 ng/ml (1.16 ng/ml to
28.26 ng/ml), P <0.05) and a final increase to 15.10 ng/ml
(2.09 ng/ml to 61.61 ng/ml) at 12 months (Figure 1B). The
levels were significantly higher than in HV (1.16 ng/ml
(1.16 ng/ml to 1.95 ng/ml) (P <0.0001, at all time points),
and at baseline and 12 months when compared with cRA
patients (1.59 ng/ml (1.16 ng/ml to 3.37 ng/ml) (botheR
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Table 2 Correlation between baseline plasma levels of
sOX40L and sOX40 in early rheumatoid arthritis and
clinical measurements
sOX40L sOX40
DAS28 score, baseline −0.039 0.152
DAS28 score, 12 months 0.027 0.209
HAQ score, baseline 0.031 0.189
HAQ score, 12 months 0.328** −0.114
SDAI, baseline −0.098 0.090
SDAI, 12 months −0.039 −0.075
CDAI, baseline −0.120 0.075
CDAI, 12 months −0.113 0.079
IgM-RF, baseline 0.518** 0.003
ACPA, baseline 0.407** 0.005
Values shown are Spearman’s rho values, with *P <0.05, **P <0.01, ***P<0.001.
CRP, C-reactive protein; DAS28, disease activity score,28 joints, CRP based;
CDAI, clinical disease activity index; SDAI, simplified disease activity index;
ACPA, anti-citrullinated protein antibodies; IgM-RF, IgM rheumatoid factor.
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Figure 2 Comparison of the ratio between sOX40 and sOX40L
in early rheumatoid arthritis (eRA) and chronic rheumatoid
arthritis (cRA). The ratio was significantly lower in patients with eRA
than in patients with cRA. Healthy volunteers are not included as
many of the measurements for both sOX40 and sOX40L were below
the level of detection. Paired data (within the eRA group) were
analyzed by the Wilcoxon signed-rank test and non-paired data were
analyzed by the Mann-Whitney U-test. Boxes represent median with
interquartile range and whiskers represent the 5th to 95th percentiles.
*P <0.05, ***P <0.001.
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n = 37); ADA, n = 39) showed that there was no signifi-
cant difference in their sOX40 and sOX40L plasma levels
during the 12-month treatment period; thus, anti-TNF
treatment seemed not to affect the shedding of the two
proteins (data not shown).
Soluble OX40L levels are connected to presence of
anti-citrullinated protein antibodies (ACPA) and IgM-RF
in eRA
We assessed whether sOX40L was associated with baseline
antibody status, clinical disease parameters (DAS28CRP,
clinical disease activity index (CDAI)) and CRP. We
divided the eRA patients into IgM-RF and ACPA positive
and negative at the time of treatment initiation. Plasma
levels of sOX40L were strongly associated with the pres-
ence of IgM-RF and ACPA at baseline. In the IgM-RF-
positive group sOX40L was 28.0 ng/ml (7.84 ng/ml to
75.48 ng/ml) versus 1.7 ng/ml (1.2 ng/ml to 3.4 ng/ml) in
the IgM-RF-negative group (P <0.0001). Similarly, we ob-
served sOX40L in the ACPA-positive group to have
23.2 ng/ml (3.6 ng/ml to 73.2 ng/ml) versus 2.7 ng/ml
(1.2 ng/ml to 6.4 ng/ml) in the ACPA-negative group
(P <0.001). This association with IgM-RF and ACPA was
still present with sOX40L plasma levels measured at
3 months after treatment initiation (both P <0.01), but not
after 12 months. Plasma levels of sOX40L in the IgM-RF-
positive group was 22 ng/ml (2.68 ng/ml to 76.53 ng/ml)
and 6.85 (1.82 ng/ml to 29.17 ng/ml) in the IgM-RF-
negative group 12 months after treatment initiation, and
no longer significant. Similarly, there was no difference in
sOX40L between the ACPA-positive group (16.01 ng/ml
(1.72 ng/ml to 60.0 ng/ml)) and the ACPA-negative group
(12.0 ng/ml (2.79 ng/ml to 130 ng/ml)) after 12 months of
treatment. Plasma levels of sOX40L did not at any time
point correlate with disease activity parameters or CRP
(Table 2).
Systemic levels of sOX40 did not show any association
with disease activity parameters, CRP, IgM-RF or ACPA
(Table 2).
The sOX40/sOX40L ratio is low in eRA and is associated
with disease activity after adalimumab discontinuation
It has been suggested that like other members of the TNF
superfamily, sOX40 and sOX40L function antagonistically
to their membrane-bound forms. We therefore calculated
the sOX40/sOX40L ratio to determine this axis in our co-
hort of eRA patients and correlated it with core disease
parameters. Because sOX40 was measured in pg/ml and
sOX40L was measured in ng/ml, the ratio was multiplied
by a factor of 1,000. The sOX40/sOX40L ratio was signifi-
cantly decreased in eRA compared with cRA throughout
the study period (all P <0.001, Figure 2). We did not calcu-
late a ratio for the HV, as many of the measurements for
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limit. Adalimumab was discontinued after the first
12 month of treatment after which time patients under-
went clinical examination at 3-months intervals for an
additional year. Neither sOX40 nor sOX40L plasma
levels were associated with change in disease activity
(data not shown). However, patients with a high sOX40/
sOX40L ratio at the time of adalimumab discontinuation
had a significantly lower DAS28CRP after 3 months of
follow up (P <0.05, data not shown). We did not observe
the same correlation in the Placebo group (P = 0.9, data
not shown). We also examined any association with dis-
ease flare and identified four patients with flare. They had
a significantly decreased sOX40/sOX40L ratio compared
with patients without flare (P <0.05, data not shown).
OX40+ T cells and OX40L + B cells accumulate in the
inflamed joints
We investigated which cells express the membrane-bound
isoforms. PBMC from eRA (n = 5), and paired SFMC and
PBMC from cRA (n = 15) were examined for expression
of OX40 and OX40L by T cells, B cells, and monocytes.
As expected, OX40 was mainly expressed by CD4 +
CD45RO+T cells in the inflamed joint compared withCD4+CD45RO T cells
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Figure 3 Peripheral blood mononuclear cells (PBMC) and synovial flu
rheumatoid arthritis (cRA) (n = 15) and mononuclear cells from PBMC
volunteers (HV) (n = 10) were examined by flow cytometry for expres
squares = peripheral blood from patients with cRA; semi-solid squares = pe
from patients with cRA; white squares = peripheral blood from healthy voluntee
cells in the synovial fluid, with CD4 + CD45RO + T-cells being more positive fo
OX40L. Paired data (PBMC and SFMC) were analyzed by Wilcoxon signed-rank
lines represent median with interquartile range and whiskers represent the 5tperipheral blood (Figure 3). The highest percent of OX40-
expressing cells, was seen on CD4 + CD45RO +T cells of
cRA SFMC (37.5% (27.1% to 44.2%)) compared with cRA
PBMC (22.9% (14.3% to 30.7%)), eRA PBMC (18.3%
(13.8% to 22.65%)) and HV PBMC (13.7% (11.2 to 18.1%))
(all P <0.001). OX40+ cells were significantly higher on
CD4 +CD45RO +T cells of cRA PBMC compared with
HV PBMCs (P <0.05). OX40+ B cells and monocytes were
only present in low numbers.
OX40L was primarily expressed by B cells and mono-
cytes, which was consistent with the fact that OX40L is
expressed mostly on antigen-presenting cells. OX40L ex-
pressing B cells were significantly increased in SFMC
from cRA patients (10.3% (4.3% to 47.3%)) as compared
with cRA PBMC (4.5% (2.7% to 10.6%)) and HV PBMC
(1.2% (0.5% to 3.2%)) (P <0.05 and P <0.001). The per-
centage of OX40L expressing B cells from cRA PBMC
was significantly increased compared with HV (P <0.01).
The percentage of B cells expressing OX40L in PBMCs
from eRA (16.7% (8.7% to 34.8%)) was also significantly
increased compared with both cRA and HV (P <0.05
and P <0.01, respectively). Generally, a higher percentage
of monocytes were OX40L + compared with B cells. A
higher percentage of monocytes from eRA PBMCs wereMonocytes
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monocytes from HV PBMCs (23.1% (2.0% to 43.6%))
(P <0.05). As mentioned above, only 5 eRA PBMC sam-
ples were analyzed, and the results should therefore be
interpreted with caution.
Discussion
The generation of immunological memory is a hallmark
of the adaptive immune system. OX40 and OX40L are
central players in providing co-stimulatory signals to
activated effector CD4+ T cells and antigen-presenting
cells during this process [7,14].
In the present study, we present the first data on the
presence of sOX40 and sOX40L in patients with early
treatment naïve RA and the association between the sol-
uble forms of these TNFR superfamily receptors and clin-
ical disease parameters. We demonstrate that patients
with early RA have altered systemic levels of sOX40 and
sOX40L compared to HV and cRA, and that the highest
levels are seen in ACPA- and IgM-RF-positive eRA. We
further had indications that the balance between sOX40
and sOX40L is associated with a risk of increase in
DAS28CRP after adalimumab discontinuation.
The elevated sOX40L levels and the gradually rising
sOX40 levels during the first year after diagnosis point
to ongoing activity in the adaptive memory system
throughout this period. By contrast, levels of sOX40 and
sOX40L were almost normalized in cRA, although the
percentage of cells expressing OX40 and OX40L was
much alike in cRA and eRA. Little is known about how
the shedding of OX40 and OX40L occurs, but the
process is well described for the TNF superfamily mem-
ber TNFα, and the process is known to be tightly regu-
lated [19]. Our results suggest that the mechanisms
involved in shedding of OX40 and OX40L in cRA are
changed as compared to eRA.
Even though the eRA patients all experienced clinical
benefit from treatment and more than 50% achieved
European League against Rheumatism (EULAR) remis-
sion [20], this was not reflected in the sOX40 and the
sOX40L levels. This could either mean that the OX40
system is upstream of TNFα-regulated processes or that
they are uncoupled processes. The latter is more likely,
as signals through the OX40 system are known to be
necessary for stable antibody response formation, in this
case rheumatoid factor and ACPA antibodies, and that
patients undergoing anti-TNF therapy are able to mount
adequate vaccine responses [21,22].
The potential of the OX40 system in generating im-
munological memory is particularly interesting in RA.
Like other studies, the OPERA study showed that RA
patients who have achieved remission can discontinue
anti-TNF therapy if intensively treated in the early phase
of disease [23,24]. This suggests the presence of awindow of opportunity in the early phase of RA. Con-
versely, a subgroup of patients has a relatively poor
prognosis. To maximize the treatment effect, it is evi-
dently of great interest to separate these two groups. In
our study, patients with high sOX40L plasma levels at
baseline and after 3 months were significantly more
likely to be positive for ACPA and IgM-RF at baseline.
At later time points this correlation was not significant.
This was not due to seroconversion, but because the
levels of sOX40L changed from baseline to 12 months
after treatment initiation in the individual patients, even
though the median value was relatively unchanged. The
strong association between sOX40L and autoantibodies,
supports the role of the OX40-system in generating
adaptive immunity. This is in line with a recent study,
showing that the OX40-system is central to ensure opti-
mal priming of B-cell to generate immunity via CD4
T-cells [25]. OX40 is expressed by activated effector T
cells and OX40L by B cells. In our study, we found both
of these molecules to be upregulated during the first
year after diagnosis. This create an optimal environment
for generation of effector T-cells to facilitate initiation of
antibody formation and maturation of long-lived plasma
cells secreting antibodies [25,26].
The importance of the imbalance between sOX40 and
sOX40L is supported by the association between the
sOX40/sOX40L ratio and disease activity after adalimumab
discontinuation. A low ratio was significantly associated
with a higher DAS28CRP score after 3 months. However,
defined flare (DAS28CRP >1.2 if DAS28CRP <3.2 or >0.6 if
DAS28CRP ≥3.2 [17]) was only observed in four out of
the 39 RA patients that discontinued adalimumab, and
the results should therefore be analyzed cautiously, until
confirmed in a larger cohort. The low flare rate is most
likely due to the short follow-up intervals combined with
an aggressive regime of intra-articular triamcinolone pre-
scribed by the OPERA protocol. The possible link bet-
ween the sOX40/sOX40L ratio and the risk of flare is, of
course, of clinical interest as these findings may help pre-
dict flare in RA patients, which is currently not possible.
In combination with the accumulation of cells expressing
OX40 and OX40L in the inflamed joints, this underscores
the potentially central role of the OX40 system in perpe-
tuating the autoimmune process in RA. These findings are
supported by studies of collagen II-induced arthritis in
mice where administration of anti-OX40L mAb amelio-
rated the disease [17].
We hypothesize that the modulation of RA disease
processes through the mechanisms exercised by the
sOX40 and sOX40L molecules could take two forms.
Soluble OX40 possibly works as a decoy receptor and
blocks sOX40L or membrane-bound OX40L from bin-
ding to membrane-bound OX40. As a result, it inhibits
proliferation and survival signals for the cells. Previous
Laustsen et al. Arthritis Research & Therapy 2014, 16:474 Page 8 of 9
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inflammatory function of inducible T-regulatory (Treg)
cells and thereby suppresses the autoreactive T cells [8].
By contrast sOX40L is more likely to act as a survival
factor in the continuous activation of T cells and B cells,
making rheumatoid factor or ACPA antibodies synthesis
possible. This gives rise to dysregulation of the generation
of immunological memory and is in accordance with our
findings in the sense that eRA has low sOX40/OX40L
ratio, reflecting the balance of a more pro-inflammatory
cellular environment in this disease.
Conclusions
In summary, we found that sOX40 and sOX40L levels
were changed in eRA and that sOX40L was associated
with IgM-RF and ACPA. Furthermore, sOX40/sOX40L
ratio was associated with increase in DAS28CRP after
adalimumab discontinuation. In addition, the number of
cells expressing membrane-bound OX40 and OX40L was
increased in RA. Overall, our findings suggest that the
OX40 system is important for the formation of key auto-
antibodies in RA and possibly associated with future
disease activities.
Additional file
Additional file 1: Figure S1. Representative plots showing gating on
OX40- and OX40L-expressing cells. Gates were set using fluorescence
minus one (FMO) controls combined with a matched isotype antibody,
thus, correcting for both uncompensated spectral overlap and unspecific
binding. T cells were gated as CD4 + CD45RO+. B cells were gated as
CD19+. Monocytes were gated using CD14. All cells were blocked using
10% heat-inactivated murine serum to avoid unspecific binding.
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